Analysis

Celestica Inc. (NYSE:CLS) Shows Promising Growth Amid Market Fluctuations

02/26/2025

Celestica Inc. (CLS:NYSE) Spotlighted for Bright Future in Tech Sector

05/09/2024

News

Investors Heavily Search Celestica, Inc. (CLS): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Celestica (CLS). This makes it worthwhile to examine what the stock has in store.

03/17/2025

Celestica: The Overlooked AI Winner

Celestica reported Q4-CY24 revenue of $2.55B (+19% YoY), with CCS segment revenue surging 30% YoY to $1.74B. Full-year CY25 revenue is projected at $10.7B (+11% YoY), with adjusted EPS expected to hit $4.75 (+22% YoY). HPS within CCS grew 65% YoY, driven by AI-driven data center and networking demand.

03/12/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Celestica Inc. (CLS) a buy, sell, or hold?

Celestica Inc. (CLS) can hold. Click on Rating Page for detail.

What is Celestica Inc.'s stock price?

The price of Celestica Inc. (CLS) is 68.98 and it was updated on 2025-04-03 13:00:13.

Is Celestica Inc. (CLS) overvalued or undervalued?

Currently Celestica Inc. (CLS) is in overvalued.

News

From:

To:

Show entries

Search:

News
Should You Invest in Celestica (CLS) Based on Bullish Wall Street Views? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Mon, Mar. 10, 2025
Celestica: A Solid Buying Opportunity Celestica is rated as a "Strong Buy" due to a 40% stock dip, presenting a golden buying opportunity for GARP investors. Despite tariff concerns, CLS's EPS growth, high operating margins, and strong demand from hyperscaler customers make the stock significantly undervalued by at least 31%. The company's transition to higher-value ODM services and robust CCS segment growth position it well for long-term stability and profitability. Sun, Mar. 09, 2025
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD - CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development - ALPHARETTA, Ga., March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) relating to CLS-AX (axitinib injectable suspension) for the treatment of neovascular age-related macular degeneration (wet AMD). Thu, Mar. 06, 2025
New Strong Buy Stocks for March 6th TAP, AVBH, CLS, FUNC and HBT have been added to the Zacks Rank #1 (Strong Buy) List on March 6, 2025. Thu, Mar. 06, 2025
Best Value Stocks to Buy for March 6th AVBH, CLS and TAP made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 6, 2025. Thu, Mar. 06, 2025

Showing 1 to 5 of 5 entries

Previous1Next

Transcripts

Show entries

Search:

Transcipts Data
Celestica Inc. (CLS) on Q4 2024 Results - Earnings Call Transcript SA Transcripts Thu, Jan. 30, 2025
Celestica Inc. (CLS) on Q2 2024 Results - Earnings Call Transcript SA Transcripts Thu, Jul. 25, 2024
Celestica Inc. (CLS) on Q1 2024 Results - Earnings Call Transcript SA Transcripts Thu, Apr. 25, 2024
Celestica Inc. (CLS) on Q4 2023 Results - Earnings Call Transcript SA Transcripts Tue, Jan. 30, 2024
Celestica Inc. (CLS) on Q3 2023 Results - Earnings Call Transcript SA Transcripts Thu, Oct. 26, 2023
Celestica Inc. (CLS) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Thu, Jul. 27, 2023
Celestica Inc. (CLS) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Thu, Apr. 27, 2023
Celestica Inc. (CLS) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Thu, Jan. 26, 2023
Celestica Inc. (CLS) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Tue, Oct. 25, 2022
Celestica Inc. (CLS) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Tue, Jul. 26, 2022

Showing 1 to 10 of 15 entries

Previous1 2Next

SEC Filings

Show entries

Search:

SEC Filings
Celestica Inc. (CLS) - PRE 14A SEC Filings 03/07/2025
Celestica Inc. (CLS) - S-3ASR SEC Filings 03/03/2025
Celestica Inc. (CLS) - 8-K - Current report SEC Filings 03/03/2025
Celestica Inc. (CLS) - 10-K - Current report SEC Filings 03/03/2025
Celestica Inc. (CLS) - SCHEDULE 13G/A SEC Filings 02/14/2025
Celestica Inc. (CLS) - 4 SEC Filings 02/10/2025
Celestica Inc. (CLS) - 4 SEC Filings 02/06/2025
Celestica Inc. (CLS) - 4 SEC Filings 02/05/2025
Celestica Inc. (CLS) - 4 SEC Filings 02/03/2025
Celestica Inc. (CLS) - 8-K - Current report SEC Filings 01/31/2025

Showing 1 to 10 of 588 entries

Previous1 2 3 4 5…59Next

Press Releases

Show entries

Search:

StockPrice Release
Clearside biomedical's lead clinical program cls-ax in wet amd and suprachoroidal delivery platform highlighted at the 2025 wet amd & diabetic eye disease summit 03/20/2025
Clearside biomedical announces successful end-of-phase 2 meeting with the fda and alignment on phase 3 plans for suprachoroidal cls-ax in wet amd 03/06/2025
Clearside biomedical announces additional data from the cls-ax odyssey phase 2b trial presented at the angiogenesis, exudation, and degeneration 2025 meeting 02/10/2025
Celestica announces 2025 annual and special meeting of shareholders 01/30/2025
Celestica announces fourth quarter and fy 2024 financial results 01/29/2025
Clearside biomedical announces multiple medical meeting presentations focused on the advantages of suprachoroidal delivery and key differentiators in its cls-ax clinical program 01/28/2025
Celestica q4 2024 financial results and conference call thursday, january 30, 2025 01/13/2025
Amar maletira appointed to celestica's board of directors 01/02/2025
Celestica announces tsx acceptance of early renewal of its normal course issuer bid 10/30/2024
Celestica announces third quarter 2024 financial results and will host virtual investor meeting 10/23/2024

Showing 1 to 10 of 101 entries

Previous1 2 3 4 5…11Next

More Headlines

Show entries

Search:

News
Here is What to Know Beyond Why Celestica, Inc. (CLS) is a Trending Stock Celestica (CLS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. 03/04/2025
Celestica (CLS) Crossed Above the 50-Day Moving Average: What That Means for Investors Celestica (CLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CLS broke through the 50-day moving average, which suggests a short-term bullish trend. 02/27/2025
3 Portfolio Worthy Stocks to Buy on the Dip: CLS, GE, JPM Pulling back from their 52-week highs, these top-rated stocks are viable options for long-term positions in the portfolio. 02/26/2025
Wall Street Analysts Believe Celestica (CLS) Could Rally 26.77%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Celestica (CLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 02/25/2025
Celestica: Fueled By Relentless Catalysts Celestica's strong Q4 performance and robust FY2025 guidance, driven by AI tailwinds and data center spending, support a "Strong buy" rating. The stock's valuation is attractive, with a DCF model indicating a 38% upside potential, even under conservative growth assumptions. Celestica's financial flexibility, low RSI levels, and significant momentum make it well-positioned for continued growth and value creation. 02/25/2025
Celestica Stock Pullback Presents Buying Opportunity Subscribers to Schaeffer's Weekend Trader options recommendation service received this CLS commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters. 02/21/2025
The Stocks And ETFs Driving Trump's Tariff Target Markets Trump's tariffs cause short-term volatility, but long-term market impact is minimal; earnings remain the key focus for investors. The three countries in questions are Canada, China, and Mexico. This blog dives into several major companies domiciled in one of those three countries. In the long-term scheme of things the fundamentals of the companies behind these ADRs and stocks are likely to be more deterministic than any geopolitical factors. 02/21/2025
Are Computer and Technology Stocks Lagging Celestica (CLS) This Year? Here is how Celestica (CLS) and Anterix (ATEX) have performed compared to their sector so far this year. 02/21/2025
3 Reasons Why Growth Investors Shouldn't Overlook Celestica (CLS) Celestica (CLS) possesses solid growth attributes, which could help it handily outperform the market. 02/20/2025
Is It Worth Investing in Celestica (CLS) Based on Wall Street's Bullish Views? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? 02/20/2025

Showing 1 to 10 of 565 entries

Previous1 2 3 4 5…57Next

Unlock

CLS Ratings Summary

Quant

Neutral

CLS Quant Ranking

Sector	Technology
Industry	Hardware, Equipment & Parts
Quant Rating	Neutral
Quant Score	3

Is Celestica Inc. (CLS) a buy, sell, or hold?

What is Celestica Inc.'s stock price?

Is Celestica Inc. (CLS) overvalued or undervalued?

Here is What to Know Beyond Why Celestica, Inc. (CLS) is a Trending Stock

Celestica (CLS) Crossed Above the 50-Day Moving Average: What That Means for Investors

3 Portfolio Worthy Stocks to Buy on the Dip: CLS, GE, JPM

Wall Street Analysts Believe Celestica (CLS) Could Rally 26.77%: Here's is How to Trade

Celestica: Fueled By Relentless Catalysts

Celestica Stock Pullback Presents Buying Opportunity

The Stocks And ETFs Driving Trump's Tariff Target Markets

Are Computer and Technology Stocks Lagging Celestica (CLS) This Year?

3 Reasons Why Growth Investors Shouldn't Overlook Celestica (CLS)

Is It Worth Investing in Celestica (CLS) Based on Wall Street's Bullish Views?

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt